Treace Medical Q3 rev +11% to $50.2M; slashes FY2025 guidance to $211-213M

TREACE MEDICAL CONCEPTS, INC.

2025-Q3 EPS reported -$0.79 revenue$150,171,000

Revenue $50.2M (+11% YoY); net loss $(16.3)M or $(0.26)/share vs $(15.4)M loss in Q3 2024.
Adjusted EBITDA loss narrowed 49% to $(2.6)M from $(5.1)M in Q3 2024.
FY2025 revenue guidance cut to $211-213M (prev $224-230M); Adj. EBITDA loss now $6.5-7.5M (prev breakeven).
CEO cites headwinds from shift to MIS procedures, softer consumer demand, and macroeconomic conditions impacting Lapiplasty.
Director Richard W. Mott retired Nov 3; Board reduced to 7 members.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.